Questions to Ask Before Hiring an AI Healthcare Dev Partner

For: COO or Head of Digital at a mid-size private healthcare or pharmacy chain who has a board mandate to digitize clinical or patient-facing operations, has already seen one failed or underperforming AI pilot, and is now vetting development partners for a production build — not a demo

Before you hire an AI healthcare software development partner, run them through a structured interview built around clinical validation, audit trails, EMR integration, PHI handling, and post-deployment monitoring — not their case study deck. The most dangerous vendors are not the ones who fail your compliance checklist. They are the ones who pass it on paper while quietly cutting the clinical validation steps that would have flagged an unsafe prescription or diagnostic output.

The questions below are the ones we wish every COO would ask before signing. They are ordered roughly by how quickly a weak vendor will start hedging.

Clinical safety and validation

1. Walk me through a production feature you built where the AI output could have harmed a patient if wrong. How did you constrain it?

Why it matters: This separates teams that have shipped clinical AI from teams that have shipped healthcare-themed CRUD apps with an OpenAI call bolted on.

Good answer: They name a specific feature — drug-interaction checks, dosage calculators, triage routing — and describe hard-coded rule fallbacks, confidence thresholds, human-in-the-loop gates, and what happens when the model is uncertain. They mention the pharmacist or clinician who signed off on the logic.

Red flag: Generic language about “responsible AI” and “guardrails.” No named clinical reviewer. No description of what the system does when it doesn’t know.

2. Where in your architecture does a deterministic rule override the model, and who decided the rule set?

Why it matters: In real clinical software, the LLM or ML model is almost never the final authority on a safety-critical decision. Drug interactions, allergy checks, and contraindications should be rule-based and auditable.

Good answer: “We use the model for extraction and ranking, but interaction checks run against a curated interaction database (e.g., a licensed pharmacology dataset) reviewed by a licensed pharmacist. The model cannot approve a dispensation the rules blocked.”

Red flag: “We prompt the model to check for interactions.” That is a lawsuit waiting to happen.

3. Show me an audit log for a past project. Redact whatever you need to.

Why it matters: A team that has actually built for HIPAA or equivalent regimes has audit logging baked in from day one — not retrofitted before go-live.

Good answer: They can show a real (redacted) log with actor, action, resource, timestamp, IP, and correlation ID, plus the retention policy and immutability guarantee.

Red flag: “We’ll add audit logs during the compliance phase.”

Regulatory and data handling

4. Which of your engineers have HIPAA training on file, and when was it last renewed?

Why it matters: HIPAA training is cheap and easy — that’s the point. A vendor that hasn’t done it is telling you healthcare is a new vertical for them.

Good answer: A named training provider, renewal cadence (usually annual), and a policy on who touches PHI vs. who doesn’t.

Red flag: “All our engineers are compliance-aware.”

5. What’s your BAA position? Will you sign one, and with which subprocessors?

Why it matters: If you’re a US-facing healthcare business, every subprocessor that touches PHI needs a Business Associate Agreement. That includes model providers.

Good answer: They will sign a BAA, they use BAA-covered cloud tenancies (AWS, Azure, or GCP under BAA), and they use model endpoints that support BAAs (e.g., Azure OpenAI, AWS Bedrock) or self-hosted models. They can list every subprocessor.

Red flag: “We’ll figure out the BAA later” or usage of consumer OpenAI/Anthropic endpoints for PHI.

6. How do you handle PHI in prompts, embeddings, and vector stores?

Why it matters: A lot of “HIPAA compliant AI development company” pitches quietly ship PHI into a vector database that isn’t under BAA, or log prompts to a third-party observability tool.

Good answer: De-identification before embedding where possible, encryption at rest and in transit, vector store hosted inside the BAA-covered environment, prompt logging scrubbed or kept inside the perimeter.

Red flag: They’ve never thought about the vector DB or the observability layer as PHI surfaces.

7. For non-US markets — how do you handle DISHA (India), NDHM, GDPR Article 9, or UAE’s health data localization rules?

Why it matters: If you operate across geographies, a US-only compliance answer isn’t enough. India’s draft DPDP rules and UAE’s health data residency requirements are stricter than most vendors assume.

Good answer: They know which of your regions require in-country hosting and can name the cloud regions and residency guarantees they use.

Integration and workflow reality

8. Which EMRs, HIS, LIS, or pharmacy systems have you integrated with in production? Named systems, not categories.

Why it matters: “We’ve integrated with EMRs” is meaningless. Epic, Cerner, Allscripts, Practo Ray, eHospital, and a custom MSSQL system that a hospital’s IT lead built in 2011 are wildly different problems.

Good answer: Named systems, integration method (HL7 v2, FHIR, direct DB, flat file SFTP), and honest commentary on the pain — because there is always pain.

Red flag: Only FHIR mentioned. In practice most Indian and Middle Eastern hospital systems are pre-FHIR.

9. Describe a workflow change you pushed back on because it would have introduced clinical risk.

Why it matters: Good healthcare vendors say no. If they’ve never refused a client request on safety grounds, they’re order-takers.

Good answer: A concrete story — “The client wanted auto-dispense on repeat prescriptions without a pharmacist check. We refused and built a one-tap pharmacist confirmation instead.”

Red flag: “We always find a way to deliver what the client wants.”

10. How do clinicians and pharmacists interact with your system? Show me the screens.

Why it matters: Clinical UX is its own discipline. Alert fatigue, one-handed use, tablet vs. desktop, glove-friendly hit targets — none of this is obvious from a Figma file.

Good answer: They’ve done shadow sessions in the actual setting (OPD, dispensary, ward) and can describe the constraints.

AI-specific engineering rigor

11. How do you evaluate model performance before and after deployment?

Why it matters: If they can’t explain their eval set, you’re paying them to guess.

Good answer: A curated eval set with clinician-labeled ground truth, precision/recall tracked per class, drift detection in production, and a rollback plan when metrics degrade.

Red flag: “We tested it and it worked.”

12. What happens when the model is wrong in production? Walk me through detection, containment, and correction.

Good answer: Confidence thresholds trigger human review, feedback loop from clinicians flows into retraining, incident response has a named on-call, and there’s a documented process for pulling a feature.

Red flag: They’ve never had to think about it.

13. Do you fine-tune, RAG, or prompt-engineer? Why did you choose that for this use case?

Why it matters: A team that defaults to fine-tuning for everything, or RAG for everything, is applying a hammer.

Good answer: They can articulate tradeoffs — RAG for evolving formularies, fine-tuning for structured extraction, prompt engineering for low-stakes summarization — and match the choice to your case.

Commercial and IP

14. Who owns the code, the model weights, the prompts, and the training data?

Why it matters: Many vendors ship “their platform” and lock you into a per-seat license on software your patients depend on.

Good answer: You own everything — source, prompts, fine-tuned weights, evaluation data. No runtime licensing on core clinical logic.

Red flag: “We retain the underlying platform IP.”

15. What’s your exit plan? If we part ways in 18 months, what do we walk away with?

Good answer: Full repo access from day one, infra in your cloud account, documented runbooks, and a defined knowledge-transfer window.

Red flag: Their cloud account, their repo, and a promise.

16. How do you price change requests once we’re past MVP?

Why it matters: Healthcare specs change — regulator issues a new guideline, a payer changes a code, a drug gets recalled. A partner that treats every change as a scope war is not a partner.

Team and continuity

17. Who specifically will be on my project, and what’s their healthcare background?

Good answer: Named engineers, named clinical advisor or pharmacist reviewer, and honesty about which team members are shared across projects.

Red flag: Senior architects in the pitch, junior engineers on delivery.

18. What’s your post-launch model — SLAs, on-call, incident response for clinical bugs?

Good answer: A tiered SLA, a named on-call rotation, a defined severity ladder where a clinical safety bug is P0, and a communicated MTTR.

How CodeNicely can help

If any of the above feels like it’s describing a partner you wish you’d hired, the relevant reference point is HealthPotli — an e-pharmacy build where the AI work centered on prescription parsing, drug-interaction validation, and pharmacist workflow, not chatbot demos. That engagement involved the exact constraints a mid-size pharmacy or clinical chain runs into: OCR against messy handwritten scripts, deterministic interaction rules layered under the AI extraction, pharmacist-in-the-loop approval, and audit trails that hold up to scrutiny.

We build with full IP ownership on your side, in your cloud tenancy, and we’ll sign the BAA. For a broader view of how we approach AI builds, see our AI studio. If your mandate also covers legacy HIS or pharmacy system modernization, our digital transformation practice is where that lives.

What we’re not: a resell-someone-else’s-platform shop, and not the right partner if you want a vendor who will build whatever you ask without pushing back on clinical risk.

The one meta-question

If you only ask one thing, ask this: “Show me the last time a clinician on your team told an engineer to stop and rebuild something.” The answer tells you whether clinical safety is a checkbox at this vendor or a culture.

Frequently Asked Questions

What certifications should an AI healthcare development partner have?

At minimum: HIPAA training on file for every engineer touching PHI, willingness to sign a BAA, and use of BAA-covered cloud and model endpoints. SOC 2 Type II is a strong signal but not sufficient on its own. For non-US work, look for familiarity with GDPR Article 9, India’s DPDP framework, and regional health data residency rules.

How do I know if a vendor’s AI healthcare case study is real?

Ask to speak to the clinical stakeholder at the reference client — not the CTO. A real healthcare build always has a pharmacist, physician, or clinical operations lead who can describe how the system changed their workflow. If the vendor can’t connect you, treat the case study as marketing.

Should I hire a healthcare-specialist AI vendor or a generalist with strong engineering?

Neither extreme. A pure specialist may be thin on modern AI engineering; a pure generalist will underestimate clinical risk. Look for a partner with at least one shipped, live clinical or pharmacy product and named clinical reviewers on staff or on retainer.

How much does it cost to build an AI healthcare product?

It depends heavily on scope, integrations, regulatory footprint, and whether you’re replacing legacy systems or greenfielding. Contact CodeNicely for a personalized assessment based on your specific clinical workflows and target markets.

Can we start with a pilot before committing to a full production build?

Yes, and you should — but define the pilot as a narrow, production-grade slice (one workflow, one integration, real users) rather than a sandbox demo. Demos pass; pilots reveal whether the vendor can handle real PHI, real EMR quirks, and real clinicians. A demo that never touches a live workflow is what caused most failed healthcare AI pilots we’ve seen.